![cccb-cbac](/web/20071116042545im_/http://cbac-cccb.ca/epic/home.nsf/images/ah_top_image.jpg/$FILE/ah_top_image.jpg)
![Naviguer](/web/20071116042545im_/http://cbac-cccb.ca/epic/home.nsf/images/ah_browse_f.jpg/$FILE/ah_browse_f.jpg)
|
![](/web/20071116042545im_/http://cbac-cccb.ca/epic/home.nsf/images/spacer.gif/$FILE/spacer.gif) |
Accueil
Publications
Recherche
2001
Intellectual Property Rights in Biotechnology: The Economic Argument (disponible en anglais seulement)
Ce document est présenté dans la langue dans
laquelle il a été fourni par l'auteur ou la
source
Prepared for
The Canadian Biotechnology Advisory Committee Project Steering
Committee on Intellectual Property and the Patenting of Higher Life
Forms
by Ronald Hirshhorn and Jock Langford
March 2001
Table of Contents
-
Executive Summary
-
Introduction
-
Section 1: The Economics of IP
-
Section 2: IPRs and Biotechnology
-
Section 3: Implications and Challenges for
Canada
-
Conclusions
-
Executive Summary
Intellectual property laws are a core component of the broad
policy framework the government has put in place to foster a
more innovative economy that will support continuing
improvements in Canadians' living standards. In the absence
of government intervention, firms would have a limited incentive
to invest in the production of knowledge since many of the
benefits accrue to others. Intellectual property laws attempt to
remedy this market failure by granting property rights that
recognize an inventor's exclusive right to make, use or sell
an invention for a fixed term. Besides stimulating the
production of new knowledge, the IP system facilitates its
dissemination. In return for a period of market exclusivity, for
example, patentees must provide a clear and complete description
of their invention in the patent application, which, in Canada,
is published 18 months after the filing date.
Governments face a number of difficult policy decisions in the
design and employment of IP policy. They must determine to what
extent to rely on IP as opposed to other policy instruments,
such R&D tax incentives and public subsidies to promote
innovation. They must also decide how provisions with respect to
such matters as the scope, length and nature of IP rights can be
set so as to maximize the benefits and reduce the costs of IP
policy. A highly protective regime that restricts access to new
technologies could reduce follow-on developments and slow the
pace of innovation. On the other hand, a weak regime may be
ineffective in promoting R&D and also impair a country's
ability to license foreign technology and attract foreign
investment. For Canada, the design of IP policy must be made
with particular attention to this country's strong economic
ties with the U.S. There is a need to consider how changes in IP
policy will affect the commercial connections - including the
strong trade and investment links and the other welldeveloped
mechanisms facilitating access to the results of U.S. innovation
- that have played such an important role in Canada's
growth.
Over recent decades, broad forces that have transformed the
overall economic environment have also brought important changes
to the IP system. First, since the early 1980s, there has been a
strong growth in patenting activity in industrialized economies.
Research suggests that a main explanation is the expansion in
research opportunities created by the technological revolution
in high-technology sectors, especially biotechnology,
information technology and software. Secondly, low-cost,
increasingly powerful information technologies have made patent
application information much more widely and easily accessible.
And thirdly, as part of broad international efforts to enhance
and spread the benefits of globalization, the disparity in
global IP standards has been reduced. WTO member countries must
now respect the TRIPs agreement that establishes minimum
standards for intellectual property protection and sets out
enforcement requirements.
The biotechnology sector, and particularly the health care
segment of the industry, is a heavy user of the IP system. This
is partly a result of the high rate of innovation in this
industry. In Canada, the U.S, Japan and the EU, biotechnology is
one of the most research-intensive sectors of the economy. With
biotechnologies, it is generally relatively easy to define a new
invention with the clarity needed to meet requirements under the
Patent Act and to permit an effective defence against
infringement. Patents are especially important to biotechnology
companies because of their highly skewed returns from investment
in R&D. Patents help firms generate the high returns on
successful biotechnology innovations that are needed to
compensate for the losses on unsuccessful R&D investments -
although, in some cases, the period of market exclusivity of a
patent, and consequently investment returns, may be
substantially reduced by regulatory approval delays and the lack
of patent term restoration. Policy developments that have
facilitated the application of patent policy to biotechnology
and that have attempted to address abuses in the use of IPRs
have also contributed to the growing importance of biotechnology
patents.
Canada has a modest, but rapidly growing biotechnology industry.
Most of the approximately 300 companies are small firms,
employing 50 or fewer workers. The industry employed just under
10,000 workers in 1997 and generated $1.1 billion in sales, half
of which came from health care products. R&D investment
amounted to over 50% of sales revenue in 1997. Canadian firms
are highly dependent on outside financing to cover R&D and
sustain operations through long product development cycles.
Patent protection is crucial in helping firms raise needed
capital. Successful biotechnology firms have effectively used
patents to attract financing, especially important venture
capital support. Patents have also provided a basis for
establishing alliances that help firms share R&D costs or
that provide the latter-stage support firms need as they
approach commercialization. Biotechnology firms generally patent
first in the U.S. and then in Canada, which is a reflection of
the greater size and importance of the U.S. market.
Among the different segments of the Canadian biotechnology
industry, patent protection is most important to health care
companies, which accounted for almost 90% of biotechnology
R&D in 1997. Environmental and aquaculture companies rely
mainly on other less costly forms of protection, including trade
secrecy. Agricultural biotech firms also utilize the Plant
Breeders' Rights Act, under which they may gain the
exclusive right to sell and produce a specific plant variety
for the purpose of selling its propagating
material.
There are unique challenges in protecting biotechnology products
against infringement. Canadian biotoech firms have to contend
with the difficulties of enforcing claims on inventions that are
reproducible and thereby simpler and cheaper to copy than
traditional technologies. Another issue of increasing importance
to Canadian biotech companies is the "transaction
costs" of negotiating and collecting licensing royalties.
As both significant buyers and sellers of intellectual property,
biotechnology have an interest in strategic alliances,
collectives and other arrangements with the potential to reduce
the costs involved in negotiating and collecting royalties and
enforcing IP rights.
There remains considerable scope for debate about the features
of an optimal IP policy for the Canadian biotechnology sector.
Recent surveys and reports have focussed on issues such as the
application of patent protection to higher life forms, the scope
of the research use defence and the methods of medical treatment
exemption, and the appropriate interface between the Patent Act
and the Plant Breeders' Rights Act. Canada’s current
IP policy is different than that of its main trading partners on
some of these issues, such as the patenting of higher life forms
and patent term restoration. The resolution of questions that
have arisen with respect to these and other matters requires a
careful weighing of economic tradeoffs, along, in some cases,
with an assessment of social and other public policy
considerations.
-
Introduction
The purpose of this paper is to provide an overview of the
economics of intellectual property (IP) and to examine the
importance of IP in general and patents in particular for the
Canadian biotechnology industry. It begins with a general
discussion of how IP fits into the framework of government
policies aimed at promoting innovation. The first section also
contains a brief discussion of the factors that must be
considered in designing an IP regime to meet the needs of a
small open economy. The second section focuses on the importance
of IP protection to biotechnology and examines recent efforts to
extend the application of IP laws to this sector. In the third
section, general considerations pertaining to IP are related to
the specific circumstances facing the Canadian biotechnology
industry. Following a brief review of key data on the Canadian
industry, there is a discussion of evidence shedding light on
the role and importance of patents in the development of
Canadian biotechnology firms. The final part of Section 3
reviews some of the specific issues that have arisen in
discussions on how to improve the application of Canadian IP law
to the biotechnology sector.
-
Section 1: The Economics of IP
Intellectual property laws are a core component of the broad
policy framework the government has put in place to foster a
more innovative economy that will sustain continuing
improvements in Canadians' living standards. Economists have
long recognized the important contribution of technological
progress to the productivity growth that has been the key to the
sustained increases in average income that industrial economies
have enjoyed over the past two centuries. Among the recent
economic studies highlighting the importance of innovation are
so-called "endogenous" growth models. These
theoretical studies explain why, because of its unique
characteristics, the new knowledge that results from research is
a particularly important source of economic growth. The critical
role of technological progress is supported by a variety of
empirical evidence. For example, one historical study, which
reviews evidence dating back to 1820 for 21 countries and back
to 1950 for another 22 economies, concludes that ". the
major engine of growth has been advancing knowledge and
technical progress, which needs to be embodied in human and
physical capital in order to have an impact".1
Economists have also long understood that, left to their own,
markets will not lead to adequate innovation. The main source of
market failure is the inability of individuals and firms to
prevent others from making use of the new knowledge they
produce. If firms cannot appropriate the full returns from
producing knowledge, they will have less incentive to invest in
knowledge-producing activities. R&D with potentially high
social returns but with low expected private returns will not be
undertaken.
Knowledge further qualifies as a public good because of its
non-rival quality; it doesn't lose its utility as it is used
and re-used. Since knowledge remains intact as it is used and it
can be transmitted at close to zero cost, there are public
benefits from the widespread sharing of knowledge.
Profit-maximizing firms, however, have no incentive to
contribute to knowledge spillovers that benefit other firms.
Studies suggest that private returns, which are the basis for
research investments, are no more than half of the social
returns to R&D. 2
Intellectual property laws attempt to remedy the market failure
in R&D markets by granting property rights that recognize
the inventor's exclusive right to make, use or sell an
invention. Inventors can apply for a patent, for example, that
will provide up to 20 years of protection for eligible
inventions that meet the tests of novelty, utility and
nonobviousness. Intellectual property rights (IPRs) increase the
extent to which the benefits of innovation can be appropriated
and thus help strengthen the incentive for private firms to
undertake R&D. This gain in dynamic efficiency3 comes with a cost because IP
protection leads the prices of goods and technology to rise
above their efficient level based on the costs of production (or
more precisely their marginal costs). There is a loss to the
economy due to the resulting underutilization of knowledge and
underproduction of goods. IP laws are beneficial because, in
general, the dynamic efficiency gains from greater innovative
activity exceed the losses in static efficiency4 from higher product and technology
prices.
Besides stimulating the production of new knowledge, the IP
system facilitates its dissemination. In return for the grant of
a period of market exclusivity, for example, patentees must
disclose their invention. A clear and complete description of
the invention must be provided on the patent application, which,
in Canada, is published 18 months after filing. Such information
dissemination is an important source of the dynamic efficiency
benefits produced by IP. The information disclosed in patents
enables other to build on earlier inventions. It also helps
avoids costly and wasteful duplication in research efforts.
IP law is only one of the instruments Canadian policymakers
employ to support the creation of knowledge and help build a
more innovative economy. The creation of IP rights is
inappropriate for basic research findings, such as new
discoveries in physics, which are important building blocks in
the advancement of human knowledge. Basic research findings
generally do not have direct industrial applicability, but they
lay a foundation for further research and subsequent inventive
activity with potentially farreaching implications for various
aspects of human wellbeing. In this case, where there is a
strong public interest in the free distribution of research
findings, the government uses subsidies to supplement existing
academic incentives for discovery and publication.5
To encourage R&D by business, in addition to IP law, the
government employs tax incentives. Indeed, Canada has a very
generous system of R&D tax incentives relative to other OECD
countries.6 With tax
incentives and business subsidies, however, part of the cost of
poor investment decisions are borne by the public at large.
Under IP, by contrast, private investors bear all the investment
risk. Entities who have invested their own funds to acquire an
IP right or who are accountable to shareholders have a strong
incentive to identify the most promising opportunities for the
development of new products and processes.
-
Determining the Features of an
Optimal IP Regime
Policymakers face a number of difficult decisions in their
efforts to design a regime that maximizes the economic
gains and minimizes the potential economic losses from IP
protection. The economic impact of IP will be
significantly influenced by the standards the government
establishes to define the legal structure of IP rights. In
the case of patents, for example, there is a need to
determine: the scope of patentable subject matter; patent
term; the breadth of patents; the nature of the patent
rights; and the nature of any exceptions that are needed
to protect the public interest. The strength of patent
protection depends on the legislative standards
established for these factors and on jurisprudential and
administrative decisions that determine how these
standards are interpreted and enforced. Administration and
enforcement are affected by a variety of factors,
including patent examination procedures, patent rules
affecting onus of proof, patent opposition rules, court
rulings regarding innoculary injunctions, infringement
awards, and custom enforcement at the border.
Strong IP protection increases the value of patents and
other IP rights, but it reduces access to patented goods
and it could significantly reduce the contribution of the
patent system to the dissemination of new research
findings. Innovation involves both the development and the
adaptation of new product and process technologies. By
increasing the strength of IP protection - by, for
example, extending the duration of patents - policymakers
increase the potential returns from innovative activity,
but they make it more costly to acquire protected
technologies. The innovation that results from the spread
of new technologies and their modification and adaptation
by subsequent users is likely to be reduced.
Moreover, in designing an IP regime that effectively
promotes innovation, policymakers must take account of the
incremental and cumulative nature of the innovative
process; existing innovations are key inputs into the
production of future knowledge. As discussed above, the IP
system contributes to the dissemination of knowledge. The
disclosure that occurs when firms patent their inventions
contrasts with the lack of information when firms chose to
instead protect their innovations through trade secrecy.
The benefits provided by the patent system, however, will
be reduced where governments establish stringent tests and
costly application processes that encourage firms to rely
on trade secrecy rather than patent protection. The IP
system's role as a mechanism of information
dissemination can also be reduced by the creation of
strong rights that result in excessively high prices for
the information that is needed for follow-on innovations.
Of relevance to the latter issue are concerns that have
been raised regarding the scope of patent rights. Concerns
about the impact of broad patent claims have been
highlighted by the U.S. government's allegation that
Microsoft is leveraging its dominance of computer
operating systems to exercise control over application
software. Many industry experts believe that
Microsoft's market power, which is partly attributable
to its strong patent rights, may have retarded the pace of
innovation in the computer industry.
The establishment of a positive innovation environment
requires that decisions with respect to such matters as
patent scope and duration reflect a careful balancing of
the incentives for initial and follow-on inventors. It
also requires the supportive application of competition
policy. While, historically, anti-trust authorities have
viewed the exclusionary rights conveyed by patents as
being at odds with competition objectives, there has come
to be a gradual appreciation that the dynamic efficiency
gains pursued through IP policy contribute to enhancing
consumer welfare, which is the ultimate objective of
competition policy. In Canada, as in the U.S., however,
competition authorities are concerned about possible
abuses resulting from overly-broad patents, especially in
network industries, and from firms' use of IP rights
to extend their market power.7 Abuse of patents may be
addressed through S. 65 of the Patent Act and S.
32 of the Competition Act, but these provisions have been
used infrequently.
-
IP Policy in a Global Economy
In a global economy characterised by growing trade and
investment and the increasing importance of multinational
enterprises (MNEs), there are additional factors that
influence the role of objectives of IP policy. In general,
small open economies that are heavy net importers of
technology and goods embodying new technologies have an
interest in weaker IP standards than countries that are
major exporters of intellectual property.8 It is also important to
consider, however, that a country's ability to imitate
and adapt foreign technologies depends on its innovative
capabilities. Countries that are importers of technology
must still build a significant R&D infrastructure
through IP and other innovation policies if they are to be
in a position to take advantage of inflows of foreign
technology.
There are other potential costs from inadequate IP laws
and enforcement mechanisms. Weak IP protection can impact
on a country's trade, foreign investment and its
ability to license foreign technology. While it is
difficult to isolate IP from all the other factors that
influence trade, investment and technology licensing, some
studies focusing on the experience of developing countries
suggest that inadequate IP policies do negatively impact
on foreign commerce.9
One study, for example, found that stronger patents
contribute to increased trade by developing countries,
especially larger and wealthier developing nations.10 In the case of foreign
direct investment, weak IP laws could reduce investment
inflows into a country, but they could also result in an
increase in investment because the alternative of
technology licensing becomes an especially risky and
unattractive option. The latter result would be consistent
with research indicating that foreign direct investment is
often a response to government policies that make it
difficult for MNEs to realize the value of their strategic
assets through market transactions. Evidence has found,
however, that U.S. multinationals are discouraged from
investing in countries with weak IP laws. The World Bank
study found that strong patent rights are particularly
important in the R&D and manufacturing investment
location decisions of multinationals in the chemical and
pharmaceutical sectors.11
For Canada, IP policy must be framed with particular
attention to this country's strong economic ties to
the U.S. As a small country, Canada's perspective on
IP policy will differ from the U.S., which is the
world's most innovative economy by most measures.
Strong IP protection will result in increased profits for
a number of U.S. manufacturers of new products and
increased prices for some goods consumed by Canadians.
Decisions on a Canadian policy, however, need to be made
in a broad context that takes account of the considerable
benefits this country enjoys from its strong trade and
investment links with the U.S. and its favourable access
to the results of U.S. innovation. These benefits have
been documented in a number of studies, including, for
example, one recent report that found R&D spillovers
from the U.S. were the major factor behind the
productivity growth of eight out of eleven manufacturing
industries examined over the period 1966 to 1991.12 Technological progress in
this country would have been slower without significant
inflows of U.S. knowledge and, also, without the stimulus
provided by the large U.S. market. Canadian inventors
recognize the importance of penetrating the U.S. market
and, in any given year, they file first with the U.S.
Patent and Trademark Office (USPTO) and file more patents
with the USPTO than with the Canadian Intellectual
Property Office (CIPO).13 An IP regime that reflects
Canada's interest as a small, technology-importing
country within the North American economic region will
support the commercial connections that have played a
major role in this country's long-term growth.
-
Recent Developments
Broad forces that have transformed the overall economic
environment, especially globalization and the information
technology revolution, have also brought important changes
to the IP system. Three developments in IP are
particularly noteworthy. First, since the early 1980s,
there has been a strong growth in patenting activity in
industrialized countries. Patent applications received by
the USPTO, which were relatively stable for much of the
postwar period, have doubled since 1984.14 A number of explanations
have been offered for the jump in patenting, including
changes in business attitudes and practices and the
emergence of more patent-friendly courts in the U.S.15 A recent study
examining Canadian experience finds that, while a number
of factors have led to the growth in patenting activity,
the most important explanation is the expansion of
technological opportunities.16 Canadian evidence supports
the "fertile technology hypothesis", which
argues that recent developments are due to the research
opportunities created by the technological revolution in
high-technology sectors, especially biotechnology,
information technology and software.
Secondly, the information disclosed in patent applications
has become more accessible, thereby strengthening the role
of the IP system as a mechanism for disseminating
information and helping to accelerate the diffusion of new
technologies. With more countries requiring the
publication of a patent application, patent information is
available to the public earlier than in the past.
Individuals can generally access patent application data
18 months from the filing date. More importantly, as a
result of new, low-cost and increasingly powerful
information technologies, patent application information
is widely and easily accessible. From their home, using
the Internet, Canadians can search the CIPO database and
also check out the more than one hundred thousand patent
applications that are filed annually in the U.S. and other
major industrial countries.
Thirdly, IP protection in developing economies has been
strengthened and the disparity in global IP standards has
been reduced.17 The
changes in IP are part of a broader global development
that has included reductions in trade and investment
barriers and other international policy reforms aimed at
enhancing and spreading the benefits of globalization. The
major vehicle for the international changes in IP has been
the 1994 WTO Agreement on Trade-Related Aspects of
Intellectual Property (TRIPs). The TRIPs agreement
requires signatories to apply the principles of national
treatment and mostfavoured nation (MFN) to intellectual
property protection. It establishes minimum standards of
protection for all forms of intellectual property -
patents, copyright, trademarks, geographical indications,
industrial designs and layout designs for integrated
circuits - and sets out measures to address enforcement.
TRIPs became applicable in 1996, but developing countries
were allowed a 4-year transition period and the
leastdeveloped countries were granted an extension until
2006.
-
Section 2: IPRs and Biotechnology
-
The Importance of IP to the
Biotechnology Sector
Biotechnology is one of the high-technology fields that
has seen an exceptionally strong rise in new innovations
and experienced rapid growth in recent years. Using new
biological tools, researchers have developed a wide range
of possibilities for using living organisms, or parts of
living organisms, to produce new products or processes.
Biotechnology has applications in many sectors, including
healthcare, agriculture, environmental protection, and
aquaculture. In healthcare, for example, research based on
biotechnology has resulted in new diagnostic tools and
treatments for cancer, atherosclerosis, osteoporosis,
asthma and AIDS.18 In
agriculture, the industry has created disease resistant
plants that are helping developing economies respond to
the food needs of their growing populations.
Biotechnology, like information technology, is an enabling
or general purpose technology. Enabling technologies open
up important avenues of research that spawn further
innovations and ultimately result in products and
processes that may significantly affect individuals'
lives. The application of steam power and electrification
are example of such major innovations with long-term and
far-reaching implications for the way economic activities
are performed and organized. There is debate about whether
recent advances in information technology and
biotechnology are breakthroughs of a similar order of
magnitude and whether they will have impacts on the growth
of industrial economies comparable to steam power,
electricity, and other past transformative technologies.19 There is no question,
however, that recent developments in information
technology and biotechnology have contributed to an
acceleration in the pace of innovation and that they have
resulted in a multitude of important new products and
processes.
A well-developed patent system is important to the
biotechnology sector in part because of the industry's
high rate of innovation. Studies that have attempted to
understand the substantial differences across industries
in the use of intellectual property protection point to
"innovativeness" as a key explanatory factor.20 Industries that are
major users of the patent system invest heavily in R&D
and are proficient at developing marketable products.
Biotechnology has the highest research intensity of any
industry. The ratio of R&D spending to total sales is
estimated at 48% in the U.S., 53% in Canada and 59% in the
EU.21 By comparison,
R&D expenditures as a percentage of value added for
all manufacturing is only about 8% in the U.S., and is
under 7% for 14 major OECD industrialized countries.22 The top five
biotechnology companies in the U.S. spent an average of
$121,400 per employee on R&D compared with an average
of $30,600 per employee for the top pharmaceutical
companies.23 A high
proportion of biotechnology workers (estimated at around
40% for Canada) is involved in basic and applied
research.24
Accordingly, much of the industry's workforce consists
of highly skilled scientists and engineers with expertise
in fields such as biology, protein chemistry, immunology,
computer modelling and bio-process engineering.25
A high rate of innovation is a necessary but not
sufficient condition for a firm to be a heavy user of the
IP system. First, not all innovations qualify for IP
protection. To be eligible for a patent, the innovation
must be novel, non-obvious to a person skilled in the
field, and have industrial applicability (i.e it must
possess "utility"). A 1996 Statistics Canada
survey of new, smaller firms in goods and services
industries - the business population that is often the
source of major new product developments - found that many
firms are engaged in innovation, but only a small portion
of this activity is directed to producing entirely new
products or processes.26
Second, not all innovations that are eligible for IP
protection are protected. Firms will only seek IP
protection if the return from their investment in
obtaining and enforcing patents or other IP rights is
likely to exceed the return from investing in alternative
means to appropriate the benefits from their inventive
activity. There is some survey evidence suggesting that
firms in many industries rely less on patents than other
sources of protection such as their R&D lead or their
possession of specialized knowledge or assets.27 Secrecy is often favoured as
the means for protecting process innovations. However, in
a large number of industries, firms have indicated they
are likely to patent their patentable inventions. One
survey found that over 80% of patentable inventions were
patented in the pharmaceutical, chemical, petroleum,
machinery and electrical equipment industries.28
With biotechnologies, as with chemicals and
pharmaceuticals, it is generally relatively easy to define
a new invention with the clarity needed to meet
requirements under the Patent Act and to permit an
effective defence against infringement. Like the
pharmaceutical industry, much of the biotechnology sector
is characterized by high-risk research that may require
several hundred million dollars and many years to
complete. In the biopharmaceutical sub-sector, substantial
further investment is required to take a new drug through
the Phase I, II and III clinical trials and prepare it for
commercialization. First-mover advantages and secrecy are
ineffective appropriability strategies in this environment
where firms must comply with a lengthy regulatory process
involving significant disclosure.
In both the pharmaceutical and biopharmaceutical
industries, most revenues come from a small number of
highly successful products. One study found, for example,
that ten "blockbuster" entities were responsible
for a major share of the profits that pharmaceutical
companies earned from the introduction of new drugs into
the U.S. market over the 1970s.29 Patents help generate the
substantial returns pharmaceutical and biopharmaceutical
firms need on their successful innovations to recoup their
total investment in R&D. The extent of these returns
may be affected, however, by whether additional patent
protection is available to compensate for time lost in the
regulatory process. In some cases, the period of market
exclusivity of a patent may be substantially reduced by
regulatory approval delays and the lack of patent term
restoration.
There are some differences in the role and importance of
IP within different segments of the biotechnology sector.
IP protection is most important in healthcare, which
includes biopharmaceuticals. This is the largest segment
of the industry, accounting for almost 70% of output in
the U.S., which is the world's largest producer of
biotechnology products.30 Firms in agriculture,
aquaculture, environmental protection and other industry
segments are less research intensive and their inventions
tend to generate much less revenue than innovations in
medical biotechnology. In these smaller segments of the
industry, firms are more likely to be discouraged by IP
costs and to rely significantly on other forms of
protection, such as first-mover advantages.
In the biotechnology industry generally, however, there is
recognition that intellectual property rights are valuable
assets that have a significant influence on firms'
competitive prospects. Patents are important in helping
biotechnology companies, especially smaller firms, raise
needed capital. They also provide emerging companies with
the secure ownership rights over new technologies that
they need to enter into joint ventures and alliances.
Patents help biopharmaceutical firms attract the interest
of major drug firms that are looking for new opportunities
to exploit technology synergies and strengthen their
competitive position. In the early 1990s, when
multinational drug companies, who were concerned about
declining revenues, went shopping for acquisitions and
partnerships, it was those biotechnology companies with
strong IP rights capable of replacing their expiring
patents that they targeted.31
-
Applying IP Policy To Biotechnology
Patent filings by biotechnology firms have increased
rapidly in recent years and biotechnology has become one
of the most patent-intensive of all industries.32 In 1999, for example, the
importance of the biotechnology industry as measured by
its share of U.S. employment amounted to only about 0.1%.
However, the 16,882 patents examined by PTO's
Technology Center 1600, which handles biotechnology
patents, represented 10 percent of all patents issued by
the PTO in that year.33
While these results are largely due to the industry's
high rate of innovation and its other characteristics
described above, they also reflect the impact of important
developments in IP policy.
To respond to the needs of the biotechnology sector, IP
protection is being extended to new subject matter and
existing IP laws are being strengthened. The 1991
International Convention for the Protection of New
Varieties of Plants (1991 UPOV Convention), for example,
strengthened protection for plant varieties. While no
country permits the patenting of human beings, inventions
involving human organs and tissues are eligible for
patenting in the U.S., Japan and Australia. Many of
Canada's trading partners, including the U.S., Japan,
Australia and the EU, patent plants and animals.
Biotechnological processes - such as the basic technique
for creating recombinant DNA - are patentable. In the EU,
new sui generis database protection has allowed gene
sequencers to contract for access to their genomic
information.
In most countries, special steps have been taken to
facilitate disclosure of patent information. For
biological inventions that cannot be adequately described
through words, the inventor may deposit a sample of the
genetic material in a facility so the physical entity can
be made available to interested parties. To facilitate
examination of gene sequences, these organisms are
disclosed in an electronic format using specialized
software. Some countries have also introduced special
rules to address infringement concerns raised by such
provisions. In Europe, for example, patentees can restrict
access to biological samples to experts approved by either
themselves or the European Patent Office (EPO). In
addition, samples from the deposit, which can only be
obtained through a formal request to the EPO, can be used
solely for experimentation and testing and cannot be
transferred to other parties.
Through IP policy, and also through competition law,
countries have been attempting to respond to concerns
about overly broad biotechnology patents that could
threaten followon innovation in the field. Where licensing
is difficult or costly, overly-broad patents may
effectively limit competitive entry into a number of
market segments. Overly-broad patents can be challenged in
the courts and can also be reviewed through
re-examination. In the U.S., for example, the Federal
Trade Commission (FTC) has focussed attention on the role
of broad biotechnology patents in facilitating
anti-competitive cross-licensing and patent pool
arrangements. The FTC is also concerned about the recent
more aggressive assertion of infringement claims, which it
believes may be part of a strategy by some biotechnology
companies to slow competitive entry into the industry.
For the biotechnology industry, one of the most
significant recent policy developments has been the
agreement among WTO countries to establish minimum
standards of IP protection. With their very high R&D
costs, its is important for biotechnology firms to market
their innovations in as many markets as soon as possible.
Global strategies, involving some combination of exports,
foreign direct investment and foreign licensing, help
firms realize the substantial economies of scale
associated with their investment in developing new
biotechnology-based products and processes. The TRIPs
agreement has made it less risky and more feasible for
biotechnology firms to pursue market opportunities in a
number of rapidly emerging economies. As a result, the
focus of major producers is increasingly shifting from
exploiting patents in national and regional markets to
developing strategies aimed at maximizing global revenues.
-
Section 3: Implications and Challenges
for Canada
-
The Canadian Biotechnology Industry
The Canadian biotechnology industry consists of some 300
mainly small, researchintensive companies. In 1997, the
year of the latest Statistics Canada survey, the industry
employed just under 10,000 workers and generated $1.1
billion in revenue, of which 90% came from biotechnology
sales. While biotechnology companies are located in all
regions, firms in Ontario and Quebec account for 70% of
sales. One quarter of the firms in the industry are
publicly traded. Over 70 percent of Canadian biotechnology
firms are small enterprises that employed 50 or fewer
workers in 1997 (Figure 1). Most of these companies are
still at the research and development stage and not yet
earning revenues. About 60% of the industry's 1997
sales were due to five firms and virtually all sales were
attributable to 50 firms.
Table 1 The Biotechnology Industry: Key Data by
Company Size, 1997
|
No. of employees
|
Total
|
|
1-50
|
51-150
|
over 151
|
|
No. of Firms
|
204
|
43
|
35
|
282
|
Revenue ($ millions)
|
231
|
183
|
721
|
1,135
|
R&D ($ millions)
|
192
|
153
|
240
|
585
|
Exports ($ millions)
|
95
|
43
|
275
|
413
|
Employees
|
3,125
|
2,397
|
4,302
|
9,823
|
Source: BIOTECanada, Canadian Biotechnology '98:
Success from Excellence, 1999.
The rapidly growing Canadian industry is a small, but
increasingly important, player in global biotechnology
markets. The United States' industry is the
world's largest, employing over 160,000 workers and
earning revenues of over $C 34 billion (in 1999). Other
significant participants are Japan and the EU, whose
member countries employed over 53,000 workers in
biotechnology in 1999. Biotechnology firms in all
countries devote a very high proportion of revenue - close
to or over 50% - to research and development. Canadian
firms have a higher R&D intensity (R&D/revenue)
than U.S. firms, but, this partly reflects the lower sales
of Canadian firms, which tend to be positioned at an
earlier stage in the product development and
commercialization process. In terms of R&D per
employee, Canadian spending is only about 60% of the U.S.
industry average.
Health care is the largest segment of the Canadian
biotechnology industry, accounting, in 1997, for almost
half the number of companies, 68% of employment and 50% of
biotech sales. Agriculture is the next largest segment of
the industry, followed by food processing. While
agriculture and food processing together account for
almost 45% of biotech sales, their combined share of
industry employment is only 19%. The other segments of the
industry - environment, aquaculture, bio-informatics - are
significantly smaller in terms of output and production
(Table 2).
Table 2 The Biotechnology Industry: Importance
of Main Industry Segments, 1997 (Percentage
Share)
|
Companies
|
Biotech Sales
|
Employment
|
R&D
|
Health Care
|
46
|
50
|
68
|
87
|
Agriculture
|
22
|
23
|
17
|
5
|
Environment
|
11
|
3
|
3
|
1
|
Food Processing
|
7
|
21
|
2
|
2
|
Aquaculture
|
4
|
1
|
1
|
0
|
Bio-Informatics
|
3
|
0
|
2
|
2
|
Other
|
7
|
2
|
7
|
3
|
Total
|
100
|
100
|
100
|
100
|
Source: BIOTECanada, Canadian Biotechnology '98:
Success from Excellence, 1999.
The relatively small biotechnology industry accounts for a
significant portion of all R&D spending by Canadian
business - over 5%. Most of the industry's
approximately $600 million in annual R&D spending is
undertaken by the health care sub-sector. Biotechnology
firms are reliant on outside sources of capital to finance
R&D and carry them through extended product
development cycles that may last ten years or more.34 Private placements and
venture capital have been the two most important sources
of outside financing. In 1999, $315 million in venture
capital was invested in Canadian biotechnology firms.
-
The Role of IP in the Canadian
Biotechnology Industry
The Canadian biotechnology industry benefits from a range
of government policies supporting innovation. The federal
government makes significant ongoing investments in
programs to build the country's science and technology
infrastructure (e.g. Canadian Foundation for Innovation),
to develop skilled human resources (e.g. Millenium
Scholarships, NSERC research grants) and to support public
sector R&D (e.g. the work of the National Research
Council). About 10 percent of the federal government's
overall research budget is devoted to biotechnology. In
addition, the sector has been able to take advantage of
various initiatives to encourage applied and commercial
research including, the federal program of R&D tax
credits, the Industrial Research Assistance Program (IRAP)
and Technology Partnerships Canada (TPC).
Among the various forms of support available to the
Canadian biotechnology industry, IP protection plays a
unique and especially significant role. Over a 5 year
period, 57% of all Canadian biotechnology firms used
patents to protect their proprietary technology, and 48%
either licensed IPRs to or acquired IPRs from another
firm.35 A recent survey
of 46 Canadian biotechnology companies found that almost
all use patents to protect their most valuable
technologies.36 Senior
biotech executives reported that acquiring a strong
intellectual property portfolio was crucial to their
efforts to raise capital and achieve competitiveness.
A recent Statistics Canada research study found that
patenting activity was one of the factors underlying the
success of those Canadian biotech companies that
experienced very rapid growth over the 1994 to 1998
period.37 The author
explains that patenting signals to the financial
community, "the novelty of [firms'] future
products, thus their exclusivity". Patents allowed
companies to raise venture capital, which helped the more
successful firms by providing them not only with needed
funds, but also management and financial services and
increased credibility.
Surveyed biotech CEOs confirm that attracting outside
investment is critical and that investors are strongly
influenced by the strength of the company's IP assets.
Patents also provide a basis for forging alliances, which
are particularly important in biotechnology. In 1997, over
two-thirds of Canadian biotech firms had entered into
R&D partnerships and almost half had entered into
marketing alliances.38
R&D alliances allow companies to exploit
complementarities in knowledge and skills and to share the
substantial costs and risks associated with the
development of new biotechnology products. Later stage
alliances enable biotech companies with strong patents to
join forces with firms possessing the financial,
manufacturing and marketing resources that are needed for
successful commercialization. Canadian firms place
importance, as well, in the strategic advantages they may
gain from strong intellectual property rights that may
dissuade other firms from developing competing products.39
Most biotechnology firms file their patent applications
first in the U.S., and then, afterwards, in Canada. This
is similar to the pattern in other industries and is a
reflection of the greater size and importance of the U.S.
market. U.S. patent protection is seen as essential for
firms to generate a significant return on their large
investment in research and product development.
Among the different segments of the Canadian biotechnology
industry, patent protection is most strongly and
consistently pursued by the health care companies.
Biopharmaceutical and other health care companies are
sensitive to the importance of patents to their financial
viability and growth. They are especially aware of the
relationship between acquiring patents on their
innovations and recouping the high R&D costs typically
associated with their area of business. On the other hand,
it seems that environmental and aquaculture companies rely
mainly on other forms of protection, including the entry
barrier provided by regulatory standards.40 The high cost of patent
protection, which discourages the filing of applications
for less important technologies or processes, is more of a
deterrent outside of health care. As compared to other
industry segments that look initially to the U.S.,
however, agricultural firms with patentable technologies
place greater importance on a Canadian patent because
Canada is a significant agricultural market.
Along with patents, Canadian biotechnology firms protect
their intellectual property with trademarks, trade
secrecy, and plant breeder's rights (PBRs). Trademarks
are generally not important assets for biotechnology
companies and most small and medium-sized firms only
register their corporate brands or domain names.41 Product trademarks are more
important to larger companies that have products that are
being marketed or approaching commercialization. All
biotechnology companies rely to some extent on trade
secrecy. For certain process-related and secondary
technologies, confidentiality agreements with employees,
other firms, and potential investors constitute the main
form of property right protection.42 In other cases, secrecy
agreements are a temporary measure to prevent disclosure
until a patent is filed.
Agricultural biotech firms that are involved in developing
propagating materials, such as seeds, can apply for
protection under the Canadian Plant Breeders'
Rights Act, which falls under the responsibility of
the Minister of Agriculture and Agri-food (unlike the
Patent Act which is the responsibility of the Minister of
Industry). Holders of PBRs rights gain the exclusive right
to sell and produce a specific plant variety for the
purposes of selling its propagating material. An exemption
under the Act, however, allows farmers to save the seeds
from protected plant varieties and replant them in
subsequent years.
There are unique challenges in protecting biotechnology
products against infringement. Canadian biotech firms have
to contend with the difficulties of enforcing claims on
inventions that are reproducible and thereby simpler and
cheaper to copy than traditional technologies. Enforcement
problems have been of particular concern to plant breeders
because of the so-called "brown-bagging"
problem. Brown-bagging occurs when a crop grown from a
pedigreed seed produces new seeds that are saved and
subsequently resold. In response, biotech firms have begun
turning to "terminator technology", which
produces harvested seeds that cannot be sown, and entering
into licensing agreements that provide farmers with access
to protected seed technology on condition that they not
sow harvested seed.
Another issue of increasing importance to Canadian biotech
companies is the "transaction costs" of
negotiating and collecting licensing royalties.
Biotechnology firms have an interest in minimizing
transaction costs from their perspective as both
significant buyers and sellers of intellectual property.
In the 1997 Statistics Canada survey, 37% of the
respondents had assigned IP rights outside of the company
over the previous 3 years, and 61% had acquired IPRs.43 One area where
transaction costs have become an important factor is in
the material transfer agreements that are commonly
negotiated between scientists and research institutes
prior to exchange of plant material. These contractual
arrangements, which have replaced the former practice of
freely exchanging materials, have raised transfer costs
and reduced the amount of material that is exchanged. In
the future, contracting may become more costly. New plant
varieties under development may contain ten or more
patented genes, each of which will have to be licensed by
those wanting to use the new plant technology. In coming
years, biotechnology companies may have an added incentive
to pursue strategic alliances and other arrangements that
reduce transactions costs. There may also be a role for
collectives, similar to those that operate in the
copyright area and that help individual creators negotiate
and collect royalties and enforcing their IP rights.
-
Improving the Design of Canadian
IP Policy
While IP protection plays an important role in the
biotechnology industry, there remains room for debate
about the contribution of specific provisions of Canadian
law. Indeed, a number of questions have been raised about
the way Canadian patent law has been adapted to the
special characteristics of biotechnology. Divergent
opinions expressed in recent surveys and reports partly
reflect differences in view about how to achieve an
appropriate balance among the tradeoffs identified in the
first section of the paper. 44 They involve different
perspectives on the specific legislative changes that are
needed to maximize the benefits that Canadians derive from
both a highly innovative domestic biotechnology industry
and the availability of reasonably priced biotechnology
products. Differences in view, however, only revolve
partly around economic issues; the application of IP
policy to the biotechnology sector also raises important
social and public policy questions that are beyond the
scope of this paper. Among the specific issues that have
been a focus of discussion are the following:
The Patenting of Higher Life Forms:
Until recently, plants and animals were not patentable in
Canada. A recent Federal Court of Appeal decision allowing
a patent on the "Harvard onco-mouse" challenges
Canada's approach in this area. The Attorney General
of Canada has sought leave to appeal this decision to the
Supreme Court of Canada. Canada’s policy differs
from that of its major trading partners such as the United
States, Japan, the European Union and Australia which
permit the patenting of higher life forms. The patenting
of higher life forms raises important social and public
policy questions. For example, Canada could be faced with
economic consequences, such as becoming a less desirable
location for biotechnology activities and investment,
should it choose a course completely different from that
of its major trading partners with respect to the
patenting of higher life forms.
The Method of Medical Treatment
Exemption:
As a result of court decisions, methods of medical
treatment cannot be patented in Canada while diagnostic
methods are patentable. A significant consideration has
been the importance of ensuring unrestricted access to
methods of medical treatments for all members of society.
This exemption, however, raises questions about the
patentability of certain biotechnology inventions, such as
gene therapies, that might be regarded as treatment
methods as well as medicines. Some have argued that there
is a need to develop statutory provisions that will
clarify policy in this area.
The Research Use Defence
Jurisprudentially-created, the research use defence
enables anyone conducting research of a non-commercial
nature to defend themselves against a suit for
infringement. The policy consideration underlying this
defence is that pure, academic research should not be
impeded. For example, the use of a patented gene by a
university researcher to determine its other functions
could be covered by the research use defence. Some have
argued that there is a need for statutory provisions
codifying this defence.
Interface Between Plant Breeders' Rights Act
and Patent Act:
Given the more limited protection available under the PBR
system, some have argued for an expansion of the patent
system to include plants. An extension of patents to cover
plant varieties would be of concern to agricultural
researchers and workers who may no longer have free access
to the varieties that they need for breeding. Although
there is a research exemption under the Patent Act, it is
not as broad as the one under the PBR Act. A related issue
is whether compulsory licenses should be created to
provide plant breeders with access to patented plant
technology and patentees access to varieties protected
under plant breeders' rights.
Third-Party Procedures:
There are some issues pertaining to patent practices that
are important to the biotechnology sector while also being
of general interest. One procedural issue is whether
Canada should allow third parties to oppose patent
applications. Japan and Australia have pre-grant
opposition procedures, under which individuals may file a
notice of opposition within a specified period of time. In
the EU, there is a post-grant opposition procedure,
allowing a notice of opposition to be filed within a
specified period of time after the patent has been
granted. Opposition procedures, depending on the manner in
which they structured, may add to the time and expense of
the patenting process. These costs must be weighed against
the benefits that may come from providing for a fuller
representation of interests in the patent-granting
process.
-
Conclusion
Intellectual property laws are a response to the failure of
markets to generate adequate incentives for innovation. By
allowing firms to more fully appropriate the benefits from their
investment in R&D, IP protection stimulates innovation.
Since patent laws require firms to disclose their invention,
they also contribute to the dissemination of information on new
technologies. Governments face a number of difficult policy
decisions in the design and employment of IP policy. They must
determine to what extent to rely on IP as opposed to other
policy instruments, such R&D tax incentives and public
subsidies to promote innovation. They must also decide how
provisions with respect to such matters as the scope, length and
nature of IP rights can be set so as to maximize the benefits
and reduce the costs of IP policy. A highly protective regime
that restricts access to new technologies could reduce follow-on
developments and slow the pace of innovation. On the other hand,
a weak regime may be ineffective in promoting R&D and also
impair a country's ability to license foreign technology and
attract foreign investment. The design of an appropriate IP
policy raises a number of complex issues that are likely to be
addressed differently by various countries. The WTO TRIPs
agreement, however, has removed some of the scope for countries
to adopt independent standards and distinct approaches toward IP
policy.
The biotechnology sector, and particularly the health care
segment of the industry, is a heavy user of the IP system. This
is partly a result of the high rate of innovation in this
industry. In Canada, the U.S, Japan and the EU, biotechnology is
one of the most research-intensive sectors of the economy. In
addition, with biotechnology, as with pharmaceuticals, patents
are important because the of the highly skewed returns from
investment in R&D. Patents help firms generate the high
returns on successful innovations that are needed to compensate
for the losses on unsuccessful R&D investments. The
importance of biotechnology patents is also the result of
important policy developments.
Canada has a modest, but rapidly growing biotechnology industry.
Most of the approximately 300 companies are small firms,
employing 50 or fewer workers. The industry employed just under
10,000 workers in 1997 and generated $1.1 billion in sales, half
of which came from health care products. R&D investment
amounted to over 50% of sales revenue in 1997. Canadian firms
are highly dependent on outside financing to cover R&D and
sustain operations through long product development cycles.
Patent protection is crucial in helping firms raise needed
capital. Successful biotechnology firms have effectively used
patents to attract financing, especially important venture
capital support. Patents have also provided a basis for
establishing alliances that help firms share R&D costs or
that provide the latter-stage support firms need as they
approach commercialisation. Biotechnology firms generally patent
first in the U.S. and then in Canada, which is a reflection of
the greater size and importance of the U.S. market.
There remains considerable scope for debate on the best and most
appropriately balanced IP policy for the Canadian biotechnology
sector. Recent reports have focussed on issues such as the
application of patent protection to higher life forms, the scope
of the research use defence and the methods of medical treatment
exemption, and the appropriate interface between the Patent
Act and the Plant Breeders' Rights Act.
Resolution of these issues requires a careful weighing of
economic tradeoffs, along, in some cases, with an assessment of
social and other public policy considerations.
1 A. Maddison in W.J. Baumol, R.J.
Nelson and E.N. Wolff (eds.), C onvergence of Productivity: Cross-
National Studies and Historical Evidence (New York: Oxford Univ.
Press),1994.
2 Based on his review of the evidence, Lester Throw
estimates the social rate of return on R&D at 66%, almost three
times the average private rate of return of 24%. See "Building
Wealth" in the Atlantic Monthly, June 1999.
3 Dynamic efficiency gains result from innovation and
investment that increase productivity growth and help raise real
income per capita over time.
4 Static efficiency requires that the economy's
resources are allocated to generate maximum social welfare. For static
efficiency, product prices should be set to allow purchases to be made
by all who place value on units of a good or service that exceeds its
cost of production (i.e. marginal cost).
5 Some economists have identified generic research as
another area where IP laws are inappropriate and alternative
incentives for innovative activity are needed. Generic or basic
technology research has been described in one report as
"need-driven, creative research on new kinds of materials, new
processes or new ways of exploring or measuring, and new ways of doing
and making thing". Lewis Branscomb et al., Investing in
Technology: Towards a Consensus Strategy for Federal Technology
Policy, John F. Kennedy School of Government, Center for Science
and International Affairs, April 1997.
6 This is discussed in Report of the Technical
Committee on Business Taxation, December 1997.
7 There remains an ongoing debate about how competition
policy should treat these and related concerns. See R.D. Anderson and
N.T. Gallini, Competition Policy and Intellectual Property Rights
in the Knowledge-Based Economy (Calgary: Univ. of Calgary Press)
1998.
8 See Y. Kotowitz, Issues in Patent Policy with Respect
to the Pharmaceutical Industry, Commission of Inquiry into the
Pharmaceutical Industry (Ottawa: Supply and Services) 1986.
9 The potential impacts may extend to exports, imports,
inward and outward foreign direct investment, technology licensing,
and alliances and joint ventures with foreign-based firms.
10 K.E. Maskus and M. Penubarti, "How Trade-Related
Are Intellectual Property Rights?" Journal of International
Economics, 39, 1995.
11 E. Mansfield, "Intellectual Property Protection,
Foreign Direct Investment and Technology Transfer," Discussion
Paper No.19, The World Bank and International Finance Corporation,
1994.
12 J. Bernstein, "Inter-Industry and U.S. R&D
Spillovers, Canadian Industrial Production and Productivity
Growth," Industry Canada Working Paper No. 19, 1998.
13 WIPO, World Intellectual Property Statistics,
Industrial Property Statistics, various years.
14 This is discussed in Iain Cockburn and Paul Chwelos,
"Intellectual Property Rights and the Transition to the
Knowledge-Based Economy," paper prepared for Industry Canada/CERI
Conference on Doing Business in the Knowledge-Based Economy,
Mont Tremblant, Sept 1998.
15 The most important development was the creation of the
U.S. Court of Appeals of the Federal Circuit (CAFC) in 1982 to handle
IP litigation. Between 1982 and 1990, under the CAFC, patentees were
successful in around 90% of cases, which compares with the success
rate of around 62% they experienced between 1953 and 1978 in
appearances before the U.S. Federal Circuit Court.
16 M. Rafiquzzaman and L. Whewell, "Recent Jumps in
Patenting Activities: Comparative Innovative Performance of Major
Industrial Countries, Patterns and Explanations," Industry
Canada, Working paper No. 27, 1998.
17 UNCTAD, World Development Report, 1998/99.
18 This is discussed in National Biotechnology Advisory
Committee, Leading in the Next Millenium, Sixth Report, 1998.
19 For example: R.J. Gordon, "Has the `New
Economy' Rendered the Productivity Slowdown Obsolete?"
Northwestern Univ. Department of Economics Discussion Paper, Evanston
Ill., 1999.
20 This is discussed in John Baldwin, Innovation and
Intellectual Property, Statistics Canada and Industry Canada,
Statistics Canada Cat. No. 88-515, 1997.
21 Data sources are: for Canada, BIOTECanada, Canadian
Biotechnology '98: Success from Excellence; for the U.S., Ernst
& Young, The 13th Biotechnology Industry Annual Report
- Bridging the Gap 99; and for the EU, Ernst & Young's Seventh
Annual Life Sciences Report 2000.
22 These numbers, which are based on data for the
mid-1990s, come from OECD, Science, Technology & Industry
Outlook 1998 (Paris: OECD) 1998.
23 M-A. Oliva and L.A. Rivera-Batiz, "Innovation,
M&As and International Competition in Technology- Intensive
Industries with an Application to Pharmaceuticals and
Biotechnology," paper prepared for Industry Canada/CERI
Conference on Doing Business in the Knowledge-Based Economy,
Mont Tremblant, Sept 1998.
24 Industry Canada, Sector Competitiveness Frameworks:
Bio-Industries, Part 1 -Overview and Prospects, 1997.
25 Ibid.
26 This is discussed in J. Baldwin and G. Gellatly, "A
Firm-Based Approach to Industry Classification: Identifying the
Knowledge-Based Economy," paper prepared for Industry Canada/CERI
Conference on Doing Business in the Knowledge-Based Economy,
Mont Tremblant, Sept 1998.
27 This evidence is quite dated and does not reflect the
impact of recent technological developments and increased
globalization. R. Levin, A. Klevorick, R. Nelson and S. Winter,
"Appropriating Returns from Industrial Research and
Development," in M. Baily and C. Winston (eds.), Brookings
Papers on Economic Activity, No. 3 (Washington: The Brookings
Institution) 1987.
28 E. Mansfield, "Patents and Innovation: An Empirical
Study," Management Science, 32, 1986.
29 Ten entities were found to account for over half the
quasi-rents realized from the introduction of 99 drugs over this
period. Henry J. Grabowski and John Vernon, "A New look at the
Returns and Risks to Pharmaceutical R&D," Management
Science, Vol. 36, July 1990.
30 This is based on data in Industry Canada, Sector
Competitiveness Frameworks: Bio-Industries, Part 1 - Overview and
Prospects, 1997.
31 M-A. Oliva and L.A. Rivera-Batiz, "Innovation,
M&As and International Competition in Technology- Intensive
Industries with an Application to Pharmaceuticals and
Biotechnology," paper prepared for Industry Canada/CERI
Conference on Doing Business in the Knowledge-Based Economy,
Mont Tremblant, Sept 1998.
32 This comes from U.S. General Accounting Office,
Deposits of Biological Materials in Support of Certain Patent
Applications, GA-01-49, October 2000.
33 Ibid.
34 Life Sciences Branch, Industry Canada, "Economic
Profile of the Canadian Biotechnology Sector," March 31, 2000
35 From presentation by Manuel Trajtenberg at Industry
Canada's "Distinguished Speaker Series", 1999.
36 Donahue, Ernst & Young, "Canadian Biotech and
intellectual Property Report 2000," report prepared for Industry
Canada, 2000.
37 Jorge Niosi, "Explaining Rapid Growth in Canadian
Biotechnology Firms," Research Paper No. 8, Science and
Technology Redesign Project, Statistics Canada, Feb. 2000.
38 BIOTECanada, Canadian Biotechnology '98: Success
from Excellence, 1999.
39 Donahue, Ernst & Young, "Canadian Biotech and
intellectual Property Report 2000," report prepared for Industry
Canada, 2000.
40 Ibid.
41 Ibid.
42 Ibid.
43 BIOTECanada, Canadian Biotechnology '98: Success
from Excellence, 1999.
44 The reference is to surveys, such as those by
BIOTECanada and Donahue, Ernst & Young, referred to above, and
also recent studies with implications for the design of IP law. The
latter include: D. Foray, "Production and distribution of
Knowledge in the New Systems of Innovation: The Role of Intellectual
Property Rights," STI Review, OECD, No. 14, 1994; and P.
Cohendet, D. Foray, D. Guellec et J. Marisse, "La gestion
publique des externalités positives de recherche," paper
prepared for Industry Canada/CERI Conference on Doing Business in
the Knowledge-Based Economy, Mont Tremblant, Sept 1998.
|